Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology

被引：31
|
作者：
Zandvliet, Anthe S. [1 ]
Schellens, Jan H. M. [2 ,3 ]
Beijnen, Jos H. [3 ]
Huitema, Alwin D. R. [1 ]
机构：
[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Med Oncol, Dept Clin Pharmacol, Amsterdam, Netherlands
[3] Univ Utrecht, Sect Drug Toxicol, Div Biomed Anal, Dept Pharmaceut Sci,Beta Fac, Utrecht, Netherlands
来源：
CLINICAL PHARMACOKINETICS | 2008年 / 47卷 / 08期
关键词：
D O I：
10.2165/00003088-200847080-00001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate the selection of dosing schedules, the development of strategies for dose individualization and the application of therapeutic drug monitoring of anticancer agents. This review discusses the role of population pharmacokinetics and pharmacodynamics in clinical oncology to enhance the efficiency of drug development and to support the development of safe and effective dosing regimens for optimal treatment of cancer patients. An overview of published population studies of investigational anticancer agents and established treatment regimens is presented.
引用
收藏
页码：487 / 513
页数：27
相关论文
共 50 条
  • [1] Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology
    Anthe S. Zandvliet
    Jan H. M. Schellens
    Jos H. Beijnen
    Alwin D. R. Huitema
    [J]. Clinical Pharmacokinetics, 2008, 47 : 487 - 513
  • [2] Linezolid pharmacokinetics and pharmacodynamics in clinical treatment
    Dryden, Matthew S.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 : IV7 - IV15
  • [3] Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
    Bruin, Maaike A. C.
    Sonke, Gabe S.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (12) : 1649 - 1675
  • [4] Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
    Maaike A. C. Bruin
    Gabe S. Sonke
    Jos H. Beijnen
    Alwin D. R. Huitema
    [J]. Clinical Pharmacokinetics, 2022, 61 : 1649 - 1675
  • [5] Population Pharmacokinetics in Oncology and Its Clinical Applications
    Widmer, Nicolas
    Guidi, Monia
    Buclin, Thierry
    [J]. PHARMACEUTICS, 2024, 16 (06)
  • [6] Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
    Papachristos, Apostolos
    Patel, Jai
    Vasileiou, Maria
    Patrinos, George P.
    [J]. CANCERS, 2023, 15 (12)
  • [7] Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis
    Zheng, Shiying Silvia
    Chong, James J. H.
    Chong, Beng Hock
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (05) : 575 - 580
  • [8] Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer
    Gambardella, Valentina
    Tarazona, Noelia
    Miguel Cejalvo, Juan
    Rosello, Susana
    Cervantes, Andres
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (04) : 449 - 456
  • [9] Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes
    Song, Jessica C.
    Stevens, David A.
    [J]. CRITICAL REVIEWS IN MICROBIOLOGY, 2016, 42 (05) : 813 - 846
  • [10] Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma
    Luu, Maxime
    Bardou, Marc
    Bonniaud, Philippe
    Goirand, Franoise
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (12) : 1503 - 1511
12345